Aurobindo Pharma USFDA approvals: arthritis drug boosts 2026

What moved the stock

Aurobindo Pharma shares rose after the company disclosed a final approval from the US Food and Drug Administration (USFDA) to manufacture and market Tofacitinib Tablets, 5 mg and 10 mg. The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Xeljanz Tablets, 5 mg and 10 mg, of PF Prism C.V. The update added to a run of USFDA-related news flow that has kept the stock in focus across recent months.

On Thursday, June 6, Aurobindo Pharma shares closed at ₹1,463.6 on the National Stock Exchange, up 1.61%. Over the past month, the shares were up 6.5%, and they had gained 20% over six months. From the beginning of the year, the stock was up 23%, based on the data cited in the same update.

The USFDA approval in focus: Tofacitinib tablets

Tofacitinib is used in arthritis treatment, and the approval covers two strengths, 5 mg and 10 mg. Aurobindo stated that its tablets are bioequivalent and therapeutically equivalent to Xeljanz, a widely referenced product in this segment. In the Indian market context, USFDA final approvals typically matter because they can expand addressable export opportunities, especially for companies with established US generics pipelines.

The disclosure did not provide launch timing, pricing, or market size for the Tofacitinib tablets in the text provided. Still, the stock reaction reflected investor attention to additional approvals for regulated markets.

Earlier USFDA approvals that also lifted sentiment

Aurobindo has reported other USFDA approvals in 2026 that were followed by share price moves. The company previously received USFDA approval for Dextromethorphan Polistirex extended-release oral suspension (30 mg/5 mL, OTC), described as bioequivalent to its reference listed drug. The product is slated to be manufactured at Unit-IV of APL Healthcare Private Limited, a wholly owned subsidiary of Aurobindo Pharma, with a planned launch in Q2 FY27.

Separately, the USFDA cleared Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), which Aurobindo said is bioequivalent and therapeutically equivalent to Ravicti Oral Liquid marketed by Horizon Therapeutics U.S. Holding LLC. The product is to be manufactured at Unit-III, with an immediate market launch planned. For this product, Aurobindo cited an estimated market size of $10.2 million for the 12 months ending February 2026, based on IQVIA MAT data.

Aurobindo also disclosed that, with the latest nod referenced in the April update, it had a cumulative 579 ANDA approvals from the USFDA, comprising 556 final approvals and 23 tentative approvals.

Plant inspections and compliance: EIR closures and observations

Beyond product approvals, inspection outcomes have remained a key watch point for investors tracking export-led pharma companies.

Aurobindo said its Unit VII inspection was concluded successfully after the company received an Establishment Inspection Report (EIR) from the USFDA. The unit was classified as VAI (Voluntary Action Indicated). The inspection had nine observations, and the EIR receipt indicated the inspection was closed.

In another update, Aurobindo had informed that the USFDA conducted an inspection at Unit V, an API manufacturing facility, and issued an EIR classifying the site under VAI, closing the inspection.

The company also disclosed that the USFDA inspected unit-III, a formulation manufacturing facility of Eugia Pharma Specialities, a wholly owned subsidiary, between January 27 and February 06, 2026. That inspection concluded with 11 observations, which the company described as procedural in nature and said would be responded to within the stipulated time.

Key data points at a glance

Stock price levels and market capitalization cited

Aurobindo Pharma’s market capitalization was cited at ₹84,321.63 crore in the June 6 update. The stock had touched a one-year high of ₹1,550 on May 21, 2026, while the 52-week low of ₹1,016.10 was hit on September 1, 2025.

In separate reports from earlier dates, Aurobindo shares were also described as touching a 52-week high of ₹1,396.60 on the BSE (with an associated 52-week range of ₹1,017.00 to ₹1,396.60 in that context). Another update stated the market capitalisation stood at ₹69,182.19 crore at that time.

Broader market context: another stock at a 52-week high

The session also saw a sharp move in CG Power, which hit a 52-week high of ₹952.15 after it commissioned an extra-high-voltage (EHV) switchgear manufacturing facility in Nashik, Maharashtra. The facility adds to the company’s S3 Unit-I facility at Ambad, Nashik, which manufactures EHV circuit breakers in the 33kV to 800kV range. While unrelated operationally, such updates often influence sector-level attention and intraday risk appetite in industrials and capital goods.

Why the USFDA news matters for investors

For Aurobindo, the cluster of USFDA approvals and inspection closures is closely tied to its US business execution and product pipeline credibility. Final approvals can expand the portfolio available for commercialisation, while EIR closures and VAI classifications reduce uncertainty around manufacturing continuity. At the same time, the presence of observations in inspections is not unusual, and the material point for markets often becomes whether inspections close without escalation.

Conclusion

Aurobindo Pharma’s latest catalyst was the USFDA’s final approval for Tofacitinib Tablets in two strengths, a development that supported the stock’s move on June 6. The company has also reported approvals for an OTC cough product with a Q2 FY27 launch plan and a specialty oral liquid with an immediate launch plan, alongside multiple inspection outcomes where EIRs signalled closure. Investors will likely continue tracking the cadence of approvals, launch execution, and further inspection outcomes as new filings translate into marketable products.